Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Ovarian Cancer
Interventions: carboplatin, gemcitabine hydrochloride; Drug
Lead sponsor: AGO Study Group; Other
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Duluth, Minnesota

Conditions: Esophageal Neoplasms, Hepatocellular Carcinoma, Colorectal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Neoplasms
Interventions: Aroplatin (Liposomal NDDP, L-NDDP); Drug
Lead sponsor: Aronex Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Thyroid Cancer, Thyroid Nodules, Thyroid Adenoma, Thyroiditis
Interventions: Not listed
Lead sponsor: Pathway Genomics; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Sarasota, Florida

Conditions: Pancreatic Cancer
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Ovarian Cancer
Interventions: Mobile Application; Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ovarian Carcinoma
Interventions: Alisertib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Berkeley Heights, New Jersey

Conditions: Heart Failure, Type 2 Diabetes, Chronic Kidney Diseases
Interventions: Virtual Consult Intervention; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide, Glargine Insulin; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions: Triamcinolone Acetonide; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Dulce Digital, Dulce Digital-Me (Automated Delivery), Dulce Digital-Me (Medical Assistant); Behavioral
Lead sponsor: Scripps Whittier Diabetes Institute; Other
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Chula Vista, California • La Jolla, California

Conditions: Type 2 Diabetes, T2D
Interventions: Insulin Efsitora Alfa, Insulin Glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 39
States / cities: Birmingham, Alabama • Sheffield, Alabama • Escondido, California + 35 more

Conditions: Hypertension, Cardiovascular Diseases, Diabetes
Interventions: Herbiotics Oral + Ent Probiotic, Placebo; Dietary Supplement
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: pegfilgrastim, carboplatin, docetaxel, erlotinib hydrochloride; Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Seattle, Washington

Conditions: Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions: Clazakizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 30
States / cities: Huntsville, Alabama • Tucson, Arizona • Glendora, California + 24 more

Conditions: Cardiovascular Diseases, Diabetes, Obesity, Hypertension
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1998
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Rosiglitazone, Metformin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 21
States / cities: Tucson, Arizona • Huntington Park, California • Los Angeles, California + 15 more

Conditions: Type 1 Diabetes
Interventions: Alprazolam, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes
Interventions: DIDGET World Web Community Reports; Device
Lead sponsor: Ascensia Diabetes Care; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Escondido, California

Conditions: Breast Cancer, Ovarian Cancer
Interventions: niraparib, everolimus; Drug
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Nasopharyngeal Carcinoma
Interventions: Spartalizumab, Investigator choice of chemotherapy; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Marietta, Georgia • Detroit, Michigan • New York, New York + 1 more

Conditions: Advanced Solid Tumors
Interventions: LCB84, Anti-PD-1 monoclonal antibody; Drug
Lead sponsor: LigaChem Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more

Conditions: Diabetic Macular Edema
Interventions: Warp 10 LED Device, Near-infrared light (NIR); Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Prediabetes
Interventions: Sitting OGTT, Standing OGTT, Sitting CGM, Standing CGM; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Pancreatic Cancer
Interventions: RAD001; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Boston, Massachusetts

Search by objective public record fields.

Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy

A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies

ctDNA in Patients With Thyroid Nodules

Validation of a Mouse Model of Pancreatic Carcinogenesis

Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)

MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Optimizing In-hospital Use of Evidence-based Therapies for Patients With Cardio-Renal-Metabolic Disease

The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes

Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders

Dulce Digital-Me: An Adaptive mHealth Intervention for Underserved Hispanics With Diabetes

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)

Probiotic Effect on Dietary Nitrate to Plasma Nitrite Production ( OPEDNPN )

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Diabetes and Heart Disease Risk in Blacks

Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

Evaluation of DIDGET TM World Reports

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Near-infrared Light (NIR) Therapy for Diabetic Macular Edema: A Pilot Study

Effects of Standing on Glycemia in Prediabetic Adults

RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer